LOAMU
JAZZ icon

Lombard Odier Asset Management (USA)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-54,000
Closed -$9.08M – 249
2018
Q3 		$9.08M Buy
54,000
+200
+0.4% +$34.4K 0.67% 44
2018
Q2 		$9.27M Buy
+53,800
New +$8.79M 0.61% 47

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s JAZZ Position: Q4 2020 in Review

Lombard Odier Asset Management (USA) sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2020, closing a stake of 5,000 shares — an estimated $713K sold.

Lombard Odier Asset Management (USA) first reported a position in JAZZ in Q2 2013 and held it in 2 quarters. The position peaked at $3.44M in Q2 2013. 437 funds tracked by Wall St. Rank hold JAZZ as of Q4 2020.

  • Lombard Odier Asset Management (USA) reported no remaining Jazz Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 5,000 Jazz Pharmaceuticals shares in Q4 2020, an estimated $713K.
  • Lombard Odier Asset Management (USA) first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Lombard Odier Asset Management (USA)'s Jazz Pharmaceuticals position peaked at $3.44M in Q2 2013.
  • 437 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2020.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q4 2020, filed 16 Feb 2021.